Blocking cytokine interleukin 10 (IL-10) at the time of immunisation enhances vaccine induced T cell responses and improves control of tumour cell growth in vivo. However, the effect of an IL-10 blockade on the biological function of macrophages has not been explored. In the current paper, a macrophage precursor cell line, U937 cells, was selected to investigate the differential expression of proteins and relevant cell signalling pathway changes, when stimulated with lipopolysaccharide (LPS) in the presence of antibodies to IL-10 or IL-10 receptor. We used a quantitative proteomic strategy to investigate variations in protein profiles of U937 cells following the treatments with LPS, LPS plus human anti-IL10 antibody and anti-IL10R antibody in 24hrs, respectively. The LPS treatment significantly activated actin-related cell matrix formation and immune response pathways. The addition of anti-IL10 and anti-IL10R antibody further promoted the immune response and potentially effect macrophage survival through PI3K/AKT signalling; however, the latter appeared to also upregulated oncogene XRCC5 and Cajal body associated processes.
Introduction
Cancer therapeutic vaccines are gradually becoming a cancer treatment modality, especially when combined with immune checkpoint inhibitors [1, 2] . Therapeutic vaccine induced T cells, especially CD8+ T cells, are able to destroy tumour cells without damaging nearby normal cells or tissues and cause less side effects compared with conventional surgery, chemo-or radiotherapy [3, 4] . Ideally, a therapeutic vaccine should elicit sufficient numbers of effector T PLOS ONE | https://doi.org/10.1371/journal.pone.0213813 March 21, 2019 1 / 22 a1111111111 a1111111111 a1111111111 a1111111111 a1111111111
lipopolysaccharide and non-essential amino acid solution were obtained from Sigma-Alderich (St. Louis, MO). Trypsin (Mass Spec grade V5280) was purchased from Promega (Madison, WI). Ultrapure water was prepared by Milli-Q water purification system (Millipore, Bedford, MA). Isobaric tag for relative and absolute quantitation (iTRAQ) 4-plex kit was purchased from AB SCIEX (Concord, Canada).
Cell line, cell culture and antibodies
Human macrophage cell line U937 was purchased from Shanghai Institutes for Cell Resource Centre, Chinese Academy of Sciences, and cultured following the protocols in the product sheets. Briefly, U937 cells were maintained in complete RPMI 1640 media (Gibco) supplemented with 10% heat inactivated FCS, 100 U of penicillin/ml and 100 μg of streptomycin/ml and were cultured at 37˚C with 5% CO 2 . Anti-IL-10 receptor (1B1.3) monoclonal antibody (MAb) for ex vivo immunisation was purchased from BioXcell (USA) and stored at -80˚C till further use. Anti-IL-10 (Cat. 506802), anti-IL-10R antibodies (Cat. 308802) for in vitro experiments were purchased from BioLedgend (Karrinyup, WA, Australia). PE conjugated anti-IL-10R antibody (Cat. 308803) was purchased from BioLegend.
Cell lysis and iTRAQ labelling of peptides
Unstimulated U937 cells were used as reference and cultured overnight. U937 cells were either stimulated with 4×10 −3 μM of LPS overnight (positive control) or treated with LPS plus 10 μg/ mL concentration of anti-IL-10 or anti-IL-10R antibodies, respectively. After the treatment, cell pellets were washed with 1 mL of cold PBS and counted, then 1×10 6 cells were lysed with 300 μl of lysis buffer (8M urea, 0.8M NH 4 HCO 3 , pH 8.0) supplemented with 10 μl of protease inhibitor cocktail (80-6501-23, GE Healthcare, Little Chalfont, UK) to prevent protein degradation. The samples were then sonicated for 30 min on ice, and then centrifuged at 12,000× g at 4˚C for 15 min. The supernatants were collected, and protein concentration in the cell lysates was measured using the Pierce BCA protein assay kit on a NanoDrop 2000 (Thermo Fisher Scientific, Bremen, Germany). Then, 500 μg of proteins were reduced with 5 μl of 100 mM DTT for 1 h at 37˚C, and subsequently alkylated with 20 μl of 100 mM IAA for 1 h at room temperature (RT) in the dark, followed by the incubation with the addition of 20 μL of 100 mM DTT at RT for 45 min. The urea concentration was reduced to below 2M by diluting the reaction mixture with MilliQ water, then the proteins digested with sequencing grade modified trypsin (Promega, Madison, WI) at 1:50 enzyme-to-substrate ratio. After 4 h of digestion at 37˚C, samples were diluted 1:4 with 50 mM NH 4 HCO 3 , 1 mM CaCl 2 and another aliquot of the same amount of trypsin was added to the samples and further incubated at room temperature overnight (~16 h). The digested samples were then acidified with 10% FA to pH<3. Tryptic peptides were desalted on Sep-Pak C18 columns (Waters, Milford, MA) and dried using Speed-Vac concentrator (Thermo Fischer, Massachussets, USA). Peptides (100 μg) from three samples were dissolved in 30 μL of 0.5 M triethylammonium bicarbonate, pH 8.5 solution, and mixed with 1 units of iTRAQ reagent that was dissolved freshly in 70 μL of ethanol. Channel 114 was used for labelling the reference (unstimulated), 115 for labelling LPS stimulated cells, 116 and 117 for labelling LPS plus anti-IL-10 or anti-IL-10 receptor antibodies, respectively. After 1 h incubation at RT, 300 μL of water was added and incubated for 30 min at RT to stop the reaction. Peptides labelled by different iTRAQ reagents were then mixed and concentrated to~200 μL, and were desalted on C18 SPE columns, dried and stored at -20 o C. Biological triplicates were prepared using the same protocol.
NanoLC tandem TripleTof MS/MS analyses
The iTRAQ labelled peptides were resuspended in 25 μL 0.1% FA in MilliQ water and analysed by LC-MS/MS on a Shimadzu Prominance Nano HPLC (Kyoto, Japan) coupled to a Triple Tof 5600 mass spectrometer (AB SCIEX, Concord, Canada) with a nano electrospray ion source, following a similar protocol reported elsewhere [20] . Briefly, ten microliters of each replicate were injected onto a trap column, followed by fractionation on a 150mm x 75μm 300SBC18, 3.5um nano HPLC column (Agilent Technologies, Australia). Linear gradients of 1-60% solvent B over 60 min at 300 nL/min flow rate, followed by a steeper gradient from 60% to 80% solvent B in 5 min were used for peptide elution. Solvent B was held at 80% for 5 min for washing the column and returned to 1% solvent B for equilibration prior to next sample injection. Solvent A consisted of 0.1% formic acid (aq) and solvent B contained 90/10 acetonitrile/ 0.1% formic acid (aq). The ionspray voltage was set to 2400V, declustering potential (DP) 100V, curtain gas flow 25, nebuliser gas 1 (GS1) 12 and interface heater at 150 o C. The mass spectrometer acquired 500ms full scan TOF-MS data followed by 20 by 50 ms full scan product ion data in an IDA mode. Full scan TOFMS data was acquired over the mass range 350-1800 and for product ion ms/ms 100-1800 with a charge state of +2 to +5. The data was acquired and processed using Analyst TF 1.5.1 software (AB SCIEX, Concord, Canada). Biological triplicates were analysed in parallel.
Protein identification and quantification
The LC-MS/MS data were imported to the PEAKS studio (Bioinformatics Solutions Inc., Waterloo, ON, Canada, version 7.0) with the assistance of MS Data Converter (Beta 1.3, http:// sciex.com/software-downloads-x2110). The database of human proteome used for the analysis in this study was downloaded from Uniprot (http://www.uniprot.org/proteomes/ UP000005640) containing 70,613 entries. De novo sequencing of peptides, database search and characterising specific PTMs were used to analyse the raw data; false discovery rate (FDR) was set to � 1%, and [-10 � log(p)] was calculated accordingly where p is the probability that an observed match is a random event. The PEAKS used the following parameters: (i) precursor ion mass tolerance, 0.1 Da; (ii) fragment ion mass tolerance, 0.1 Da (the error tolerance); (iii) tryptic enzyme specificity with two missed cleavages allowed; (iv) monoisotopic precursor mass and fragment ion mass; (v) a fixed modification of cysteine carbamidomethylation; and (vi) variable modifications including iTRAQ (for cell protein quantitation only), lysine acetylation, deamidation on asparagine and glutamine, oxidation of methionine and conversion of glutamic acid and glutamine to pyroglutamate.
For iTRAQ quantification, peptides with confidence � 99% were used in ProteinPilot 5.0 software (AB SCIEX, Concord, Canada). The mass error tolerance was set to 0.1 Da, and the peptide score threshold (-10lgP) was set to that corresponding to 1% FDR. The results of differentially expressed proteins were validated sequentially by the following criteria, the proteins must contain at least one unique high confident peptide, the proteins have a P values < 0.05 and FDR � 1%, and the fold change of proteins � 1.5. To be less restrictive in the identification of proteins with altered relative abundance in treated cells with respect to the control (unstimulated) group, a protein was included in the analysis when it was confidently identified in at least two biological replicates. that randomly occurs. Chromosome cytoband-based enrichment analysis was used to identify the genomic regions, where the input genes were significantly enriched using all the genes in these regions as background. Similar procedures were adopted to elucidate enriched gene ontology terms and pathways. In these enrichment analyses, all human genes in ToppFunc were used as background to calculate statistical significance. In addition, the Benjamini-Hochberg method implemented in ToppFunc was used to further exclude false negative results. A P-value <0.01 was adopted as the cutoff for enriched pathways and gene ontology.
Protein-protein interaction (PPI) analysis
Interactions among significantly regulated proteins were predicted using STRING [22] . STRING provides a critical assessment and integration of protein-protein interactions from multiple resources, including direct (physical) as well as indirect (functional) associations. A spring model to generate the network images. All resources were selected to generate the network and 'confidence' was used as the meaning of network edges. Neither the 1 st nor 2 nd shell of the PPI was included in this study. Protein without any interaction with other proteins was excluded from the network of this study.
Pathway analysis
The proteins determined to be differentially expressed were imported in Ingenuity Pathway Analysis (IPA; Qiagen, Redwood City, CA). In pathway analysis, the up-/down-regulation of key regulators identified in different treatments were used to predict the activation/inhibition of signalling pathways. Significance of the activation or inhibition of pathways predicted by the analysis was tested by the Fisher Exact Test P value, considering only the predictions with significant P value of <0.05 and a regulation z-score of <− 2 or >2 for inhibition and activation, respectively.
Results

Quantitative proteomic analysis reveals differential protein expression in U937 cells treated with LPS, LPS+anti-IL-10 or anti-IL-10 receptor antibodies
To reveal the molecular insights underlying the immunisation enhancement of blocking IL-10, iTRAQ 4-plex labelling in conjunction with nano-LC-MS/MS was used to assess the differential expression of the proteome of U937 cells. A workflow for the preparation and analysis is shown in Fig 1A. U937 cells were cultured for 16hrs with different treatments and untreated cells were used as controls. In total, iTRAQ analysis was used in twelve sets of experiments (biological triplicates), i.e., using 114 for labelling controls, 115 for LPS stimulation, 116 and 117 for LPS stimulation in conjunction with anti-IL-10 or anti-IL-10 receptor antibodies ( Fig  1A) . Similar initial amounts of extracted proteins were digested, labelled and mixed to generate three replicates for nano-LC-MS/MS analysis. As shown in Fig 1B, there were 866, 869 and 831 proteins from 174, 186 and 190 protein groups identified in the triplicates, respectively, including both labelled and unlabelled proteins. The detailed information of protein identification is recorded in S1 Table. The comparison among the triplicates showed that 585 proteins were mutually identified (Fig 1B) . After protein validation as described in Method, there were 236, 255 and 244 iTRAQ-labelled proteins detected in the samples with LPS stimulation, LPS plus anti-IL-10 antibody or anti-IL-10R antibody treatments, respectively (S2 Table) . Of these quantifiable proteins, 234 proteins were identified in at least two replicates (Fig 1C) . The fold-change values of these proteins with respect to untreated proteins and relevant protein annotations were shown in S2 Table. The hierarchy clustering result of quantitative analysis were displayed in S1 Fig Three replicates consistently showed that there were more significantly regulated proteins (fold-change greater than ±1.5) with LPS treatment only, than those with additional anti-IL10 or anti-IL10 antibody (S2 Table) . In terms of gene oncology and pathway analysis, only those proteins showing significant quantitative variation consistently across biological triplicates were taken into consideration (inconsistency was highlighted in S2 Table) ; the accessions and the foldchange values of these proteins were also recorded.
LPS treatment activated cell matrix formation and suppressed the signalling of Rho family proteins
The gene oncology terms of significantly regulated proteins due to the LPS treatment were analysed with detailed information provided in S3 ). Similarities can be observed for the enrichments of GO terms between up-and down-regulated proteins, most of which origin from extracellular vesicular exosome and cytosol; they relate to viral transcription, translation, viral life cycle, SRP-dependent co-translational protein targeting to membrane, nuclear-transcribed mRNA catabolic process and so forth, with molecular functions of RNA binding and structural constituent of ribosome. The down-regulated proteins had lower P-values for these mutually regulated GOs. The viral process, unfolded protein binding, glycolytic, glucose and carbohydrate metabolic process were significantly suppressed, as they appeared to be more enriched in down-regulated proteins; while RNA metabolism, protein folding, cellular component movement, gene expression, MHC class I protein binding and platelet degranulation seemed more stimulated in U937 cells due to LPS treatment. The protein-protein interactions among the significantly regulated proteins were investigated, to assess the correlations among them (S3 Table) . Fig 2B shows the PPI network with a total of 99 nodes and 661 edges, which has significantly more interactions than expected (the expected number of edges are 218 using Lambda calculation [23] ). There was a cluster of ribosomal proteins (e.g., RPL4, 5, 6, 14, 23 and 28 etc.) interacting with each other, and they interplay with other nodes mainly via EIF4A1, NME2, NCL and SLC25A5. The proteins with most interactions were mainly located in the central cluster of network, including heat shock proteins (HSP 10, 27, 60, 70 and 90), glyceraldehyde-3-phosphate dehydrogenase, valosin containing protein, protein disulphide isomerase family A, enolase 1, ATP synthase, thioredoxin, malate dehydrogenase 2, transketolase, prolyl 4-hydroxylase, aldolase A and peroxiredoxin 6, many of them are enzymes.
The GO enrichment of upregulated proteins was further investigated in terms of biological processes (Fig 3A) . There are 38 genes actively involved in negatively regulating megakaryocyte differentiation (GO:0045653, corrected P-value = 5.85E-33). We found 19 and 18 genes with differential expressions that play roles in the regulation of immune system development (GO:0002520, corrected P-value = 4.61E-11) and regulation of immune system process (GO:0002682, corrected P-value = 5.17E-7), respectively (S4 Table) . There were 16 genes highly associate with negative regulation of immune system process (GO:0002683, corrected P-value = 1.53E-13). A total of 15 genes involved in DNA replication-dependent nucleosome organisation and assembly were identified with a corrected P-value of 2.54E-30. Besides, nucleosome and chromatin related pathways are also enriched (S3 Table) . There were 16 KEGG pathways enriched post the treatment with the corrected P-values below 1.44E-2, such as systemic lupus erythematosus, alcoholism, viral carcinogenesis, ribosome, glycolysis and core module involving three-carbon compounds, etc. (Fig 3B) .
The integrative pathway analysis revealed that the RhoGDI, EIF2, death receptor and 14-3-3 signalling pathways were significantly modulated. Fig 3C shows that the downregulation of Rho family proteins leads to the inhibition of Rho-GDP interaction, which consequently suppresses downstream regulators, including CDC42, ROCK and RAC, as well as the interactions among DGKZ, PIP5K, RhoGDI, RAC and GDP. Eventually, the polymerisation of actin in cytoplasm is inhibited due to the downregulation of ARP2/3. However, as the contents of cofilin, ERM and F-actin are elevated, the stabilisation and linkage of action and cytoskeletal reorganisation are therefore activated. Within the nucleus, the inhibition of CBP/P300 is suggested. Other three pathways are shown in S1 File. On EIF2 signalling pathway, many elongation factors are activated, thus the translation is enhanced. Because of the elevated level of 14-3-3 protein, ERK1/2, p90RSK and GSK3 are activated on the 14-3-3 mediated pathway, which causes the upregulation of TAU; in the nucleus, BAX and ELK1 are activated. In terms of death receptor signalling, CASP3, 6, 9 and 7 were inhibited yet the DNA repair was enhanced, leading to the suppression of cell apoptosis. Cell shrinkage is activated due to the upregulation of actin.
Anti-IL-10 antibody enhanced immune response via inducing the expression of more heat shock proteins (HSPs)
The GO enrichments of proteins with significant regulations with LPS in conjunction of anti-IL10 antibody treatment were comparatively displayed in Fig 4A, with details of GO information listed in S3 Table. It can be found that the mutually enriched terms were more significant in up-regulated protein group, which were different from those treated by LPS only (Fig 3A) . The extracellular vesicular exosome and cytosol were the top two most enriched cellular component terms, similar to that of LPS treatment only. Chaperone binding, protein binding and stabilisation, ATPase activity, RNA binding and ATP catabolic process were more significantly suppressed; de novo posttranslational protein folding, microtubule-based process and protein polymerization appeared to be enhanced. The glycolytic, gluconeogenesis and carbohydrate metabolic processes became less significant with the addition of anti-IL10 antibody.
The significantly regulated proteins interact in a way displayed in Fig 4B, where 97 nodes and 661 edges can be determined; it has a P-value less than 10 Table) compared to LPS treatment, including innate immune response in mucosa (corrected P-value = 3.16E-10), mucosal immune response (corrected P-value = 4.40E-9), organ or tissue specific immune response (corrected P-value = 6.21E-9), innate immune response (corrected P-value = 1.61E-5), humoral immune response (corrected P-value = 2.23E-5), immune response (corrected Pvalue = 2.18E-3) and defence response (corrected P-value = 3.42E-3), which potentially resulted from the elevation of HSPs. Furthermore, three biological processes in response to bacteria were significantly detected, including antibacterial humoral response, defence response to Gram-positive bacterium and defence response to bacterium (S4 Table) , which were not present with LPS only treatment. There were two more HSP related processes that emerge with the anti-IL10 antibody treatment, i.e., chaperone-mediated protein transport involved in chaperone-mediated autophagy and autophagy translocation complex disassembly. More RNA relevant processes, such as regulation of mRNA stability, RNA replication, viral RNA genome replication and regulation of RNA stability, became significant. Negatively regulations of tumour necrosis factor superfamily member 11 production and supermolecular fibre organisation seems to be additionally activated by anti-IL10 antibody (S4 Table) . There were many metabolic processes that became less significant, such as NADH, NAD, ATP, NADP and a few pyridine and purine relevant processes. In addition, five actin-involved processes reduced their significance, including organisations of filament and cytoskeleton, filament-based process, rod assembly and filament capping.
It appears that the anti-IL10 antibody significantly modulated the death receptor signalling (Fig 5A) compared to LPS only treatment (S1 File). This was mainly caused by the differential expression levels of ARHGDIB (Rho GDP-dissociation inhibitor 2), which showed downregulation in LPS only treatment, but upregulation with the presence of anti-IL10 antibody. As a result, apoptosis process was more activated with the addition of anti-IL10 antibody. The 14- 3-3 signalling pathway was modulated in a comparable manner to LPS only treatment, which thus activated BAK and ELK1 within the nucleus (S1 File); 14-3-3 protein content was more elevated, and the higher abundance of PLC activated DAG. These two factors also contributed to the modulation of protein kinase A signalling (S1 File), where PKAr and PKAc were activated, thus cytoskeletal regulation was suppressed, yet histone H1 and H3B were upregulated in nucleus.
Anti-IL-10R antibody modulated PI3K/AKT signalling to potentially effect cell survival
There were 43 proteins quantified as significantly down-regulated, while only two GO terms were found be enriched with anti-IL-10R antibody, i. Table. The number of nodes (76) and edges (390) were much less than those of U937 cells treated with LPS plus anti-IL10 antibody or LPS only, yet still representing intensive interactive network. The group of ribosomal proteins became less clustered due to less members identified, so were the central nodes that had less interactions identified. The HSPs, including HSP27, 70 and 90, were largely connected nodes though less than anti-IL10 antibody treatment. The nucleophosmin (NPM1), guanine nucleotide binding protein (GNB2L1) and cyclophilin A (PPIA) were newly identified as major nodes in this network, while VCP and MIF were missing in comparison with anti-IL10 treatment ( S3B Fig). LPS stimulated U937 cells treated with anti-IL10 or anti-IL10R antibody showed similar amounts of enriched biological processes, which were remarkably less than those of LPS only treatment (S2A and S2B Fig) . There were several Cajal body relevant biological processes enriched uniquely due to proteins significantly upregulated with anti-IL10R antibody treatment compared to LPS plus anti-IL10 antibody or LPS only treatment, with positive regulation of protein (corrected P-value = 3.42E-4) and telomerase RNA localization to Cajal body (corrected P-value = 3.42E-4) being the most representative processes. In addition, protein localisations to nucleoplasm and nuclear body, protein refolding and formation of translation preinitiation complex processes were more representative in U937 cells treated with anti-IL10R than anti-IL10 antibody. The pathway analysis shown in Fig 5B suggests the PI3K/AKT signalling was significantly modulated, where AKT was activated by the upregulation of HSP90. None of other upstream regulator of AKT was largely influenced by the treatment. The downstream factors including MCL1, eNOS and 27KIP1 were accordingly enhanced, which in turn activated macrophage survival, production of NO and cell cycle progression (function in conjunction with 14-3-3), respectively. Other regulators, such as GSK3, FKHR, BAD, c-Raf and JIP1 etc., were suppressed. Consequently, the energy storage was activated because of GYS activation and the contribution of CCND1 to cell cycle progression; cell survival was suggestive with the upregulations of both BCL-2 and BCL-XL.
Previously, we demonstrated that blocking IL-10 signalling with an anti-IL10R antibody at the time of immunisation enhances vaccine-induced T cell responses [4] . We also demonstrated that LPS treated human PBMCs secreted more IL-12 in the presence of anti-IL-10 antibodies [19] . To further confirm that immune response would be enhanced by the application of anti-IL10R or anti-IL10 antibody, IL-6 or IL-12p40 were measured 24hrs post the treatments of U937 or mouse PBMCs (S4 Fig). The ELISA results clearly showed that IL-12p40 of PBMCs were significantly elevated by the addition of anti-IL10R or anti-IL10 antibody (S4A 
Discussion
The iTRAQ labelling in conjunction of LC-MS/MS found that poly(rC) binding protein 1 (PCBP1) was significantly up-regulated with LPS treatment (see S2 Table) . and adenylate cyclase-associated protein 1 [34] , which suggests that the dynamics of filament was remarkably altered; this can also be predicted from the RhoGDI pathway modulation shown in Fig 3C. The interactions between herpesvirus and the actin cytoskeleton of the host cell and actin-regulating Rho GTPase play important roles in virus entry and replication [35] , thus modulation of RhoGDI signalling may contribute to the interplay between LPS and the cell matrix. Besides HSP90 (with ATPase activity [36] ) and ATP synthase, ATP related proteins showed up-regulation, for example, proteasome 26S subunit acts a regulator in the ATPdependent degradation of ubiquitinated proteins [37] ; valosin containing protein is involved in the formation of the transitional endoplasmic reticulum, which generates vesicle bubbles with the assistance of ATP [38] ; and chaperonin containing TCP1 guides protein folding post ATP hydrolysis [39] . Together this suggest that the energy consumption within the cells increased as more depletion of ATP occurred due to the LPS treatment, which is also supported by the enriched glycolysis and other energy production KEGG pathways (see Fig 3B) .
Glutathione transferase Omega 1 (GSTO1) were significantly upregulated in three treatments (see S2 Table) . It has recently reported that GSTO1 plays a critical role in the proinflammatory response of macrophages to LPS [40, 41] ; in addition, the genetic knockout of GSTO1 in a mouse model remarkably reduced the pro-inflammatory response in three inflammatory disease models [42] . Our study strongly suggests that gene expression of GSTO1 might also positively correlate with pro-inflammation in U937 cells stimulated by LPS, and the use of anti-IL-10 and anti-IL-10R antibodies were not able to influence this correlation.
The upregulation of Rho GDP-dissociation inhibitor 2 (ARHGDIB), known to play crucial role in the regulation of the GDP/GTP exchange reaction [43] , was observed in U937 cells in the presence of anti-IL-10 or anti-IL-10R antibody (see S2 Table) . ARHGDIB was found to show significant overexpression in COS-7 cells with the infection of enteropathogenic E. coli intensities. The activation or inhibition of certain signalling was shown in orange or blue, respectively. Lines connecting the proteins represent known interactions, and arrows indicate the directions of up-/down-stream regulations.
https://doi.org/10.1371/journal.pone.0213813.g005 [44] . It has been reported that elevated ARHGDIB was able to attenuate HIV-1 infection via negatively regulating the replication of HIV-1 [45] . Its upregulation was also identified in the response of the mouse nervous system to alpha herpesvirus infection at the latency and reactivation stages [46, 47] , while its downregulation appears to be associated with herpesvirus entry and replication [48] . A recent report indicated that ARHGDIB produced by apoptotic T-cells can inhibit the growth of Mycobacterium tuberculosis and enhance the apoptosis of M. tuberculosis-infected human macrophages [49] . The addition of recombinant ARHGDIB to monocyte-derived macrophages resulted in the reduction of IL-10 secreted into the supernatant [49] . Our study suggested that additional anti-IL-10 or anti-IL-10R antibody further activated the pathway to produce more ARHGDIB in response to LPS stimulation.
Significant elevated level of 14-3-3 protein was only detected in the cells treated with additional anti-IL-10 antibody (see S1 File), which contributed to the presence of YWHAE and YWHAB on the PPI (see Fig 4B) , suggesting tyrosine 3-monooxygenase/tryptophan 5-monooxygenase signalling was potentially activated [50] . 14-3-3 protein was found to negatively affect parainfluenza virus particle formation through interacting with PIV5M protein to reduce the budding of virus [51] . Also, it has been found that 14-3-3 protein is able to regulate the host inflammatory response to viral and bacterial infections through interaction with Tolllike receptors [52] [53] [54] . Thus, the addition of anti-IL-10 antibody could induce U937 cells to generate more immune response towards LPS stimulation via expressing higher concentration of 14-3-3 proteins.
PI3K/AKT pathway has been found to signal with multiple receptors, such as insulin receptors [55] , pathogen recognition receptors [56] and cytokine receptors [57] , thus it regulates macrophage responses by modulating the activation phenotype [58, 59] . Previous studies also pointed out that this pathway plays critical roles in macrophage biology and inflammatory disease regulation, via the regulations of inflammatory cytokines [59] , miRNAs [60] , together with molecular functions including phagocytosis [61] , autophagy [62] , and cell metabolism [63] . In this study, significant activation of this pathway was identified with the treatment of anti-IL-10 or anti-IL-10R antibody led by the upregulation of AKT, compared to LPS treatment only (see Fig 5B and S1 File) . Consequently, macrophage survival might be increased to eliminate pathogens through phagocytosis. Meanwhile, the polarisation of M1 and M2 might also be activated [64, 65] .
The upregulations of histone cluster 1 and 2 were identified with significance in the treatment with anti-IL-10 or anti-IL-10R antibody. This protein family is one of the core components of the nucleosome and has important function in transcription regulation, DNA repair, DNA replication and chromosomal stability [66] . Thus, its upregulation suggests increased activity of the nucleosome, which is in accordance with the higher abundance of elongation factors detected by LC-MS/MS; as a response, there was elevated level of TRIM28 expressed in cells that functions as transcription suppressor [67] .
XRCC5 was significantly upregulated only in the presence of anti-IL-10R antibody and downregulated remarkably in LPS only treatment. XRCC5 is an ATP-dependent DNA helicase mapped to chromosome 2q35 and has been suggested as a potential chronic obstructive pulmonary disease susceptibility gene [68] . Other studies reported that XRCC5 promoted colon cancer growth through modulation of COX-2 signalling [69] ; potentially associated with the development of systemic lupus erythematosus [70] ; and related to hyper proliferation and resistance to apoptosis, genomic instability, and tumorigenesis [71] . Furthermore, Cajal body relevant processes were enriched in U937 cells treated with LPS plus anti-IL-10R antibody. It has been reported that Cajal body formation was induced in vitro by the overexpression of telomerase [72] and a few Cajal body-localised small nucleolar RNP components showed significantly higher levels in cancer [73, 74] , indicating Cajal body might relate to cancer progression. These studies suggest that the upregulation of XRCC5 and Cajal body related proteins observed in this study, caused by the addition of anti-IL-10R antibody, might lead to oncogenic phenotypes.
Conclusions
In summary we demonstrated that U937 cells (a macrophage precursor cell) when stimulated with TLR ligand 4, LPS, in the presence of anti-IL-10 or anti-IL-10 receptor antibodies, activated more immune-related signalling pathways than without IL-10 signalling blockade. This outcome may not only lead to higher vaccine induced immune responses but may also change the function of tumour infiltrating macrophages within the tumour microenvironment, contributing to better tumour growth control. Both antibodies enhanced macrophage survival via PI3K/AKT signalling. However, the application of anti-IL-10R antibody requires further study, as its usage might activate oncogene XRCC5. Ongoing studies that analyse the function of tumour residential macrophage is warranted when immunisation and temporal IL-10 signalling blockade is used to treat cancer patients. 
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